Argenx, the biotechnology company known for its work in autoimmune diseases, has experienced an eventful range of ups and downs. One of the company's flagship drugs,
Vyvgart, saw impressive sales across MG and CIDP treatments, leading to an outperformance of expectations and a high-velocity rally in the company's share price. The CEO of argenx has subsequently stepped down and handed over control to operating chief,
Karen Massey. Facing backlash from pulling out of
UplighTED, the phase 3 studies for efgartigimod SC used in treating thyroid eye disease, the decision led to a share price pullback. However, rising optimism from analysts has been observed due to the FDA's priority review of Vyvgart and the company’s overall successful commercial execution. Also noteworthy is the expansion of
argenx’s partnership with
Fujifilm for Vyvgart production in the US, accents further promise to the company's positive trajectory despite adversities. However, argenx faces stiff competition from Amgen, which recently received European approval to challenge the autoimmune market.
argenx News Analytics from Fri, 06 Jun 2025 07:00:00 GMT to Sat, 21 Feb 2026 19:19:49 GMT -
Rating 8
- Information 7
- Rumor -5
